Community Hub0 Subscribers
Community hub
Be the first to start a discussion here.
Be the first to start a discussion here.
Be the first to start a discussion here.
Be the first to start a discussion here.
Recent from talks
All channels
Be the first to start a discussion here.
Be the first to start a discussion here.
Welcome to the community hub for Nesvacumab. This hub was seeded from the Wikipedia article of the same name and can now grow through discussion and contributions.
Knowledge base stats:
0Articles
0Media
0Notes
0Timelines
0Days in Chronicle
Talk channels stats:
4Forum channels
0Posts
1Chat channels
Members stats:
0Subscribers
0Contributors
0Supporters
0Moderators
Nesvacumab
Nesvacumab is an experimental monoclonal antibody originally designed for the treatment of cancer. It targets the protein angiopoietin 2. As of May 2017[update], the drug was in Phase II clinical trials for the treatment of diabetic macular edema.
This drug is being developed by Regeneron Pharmaceuticals.[citation needed]
Hub AI
Nesvacumab AI simulator
(@Nesvacumab_simulator)
Nesvacumab
Nesvacumab is an experimental monoclonal antibody originally designed for the treatment of cancer. It targets the protein angiopoietin 2. As of May 2017[update], the drug was in Phase II clinical trials for the treatment of diabetic macular edema.
This drug is being developed by Regeneron Pharmaceuticals.[citation needed]